Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03967093 · ClinicalTrials.gov registry record · Phase 1
A Study of BXQ-350 in Children and Young Adults With Relapsed Solid Tumors
A Phase 1 study, sponsored by Bexion Pharmaceuticals.
- Terminated
- Registry status
- Phase 1
- Development phase
- 9
- Enrollment target
NCT03967093 is a Phase 1 study that was terminated before completion, run by Bexion Pharmaceuticals. The registered enrollment target is 9 participants.
The verdict
NCT03967093, a Phase 1 study, was terminated before completion, sponsored by Bexion Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 9 participants
- Enrollment target
Study Summary
This study will evaluate the safety of BXQ-350 and determine the maximum tolerated dose (MTD) in children and young adults with relapsed solid tumors, including recurrent malignant brain tumors. All patients will receive BXQ-350 by intravenous (IV) infusion. The study is divided into two parts: Part 1 will enroll patients at increasing dose levels of BXQ-350 in order to determine the MTD. Part 2 will use the MTD to further assess the safety of BXQ-350 as well as preliminary anti-tumor activity.
Interventions
- DRUG BXQ-350
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2019-04-15 |
| Est. Completion | 2020-01-17 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03967093
The ClinicalTrials.gov registry entry for NCT03967093 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bexion Pharmaceuticals, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which BXQ-350 is the first listed.
NCT03967093 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03967093 about?
NCT03967093 is a clinical study titled "A Study of BXQ-350 in Children and Young Adults With Relapsed Solid Tumors". This study will evaluate the safety of BXQ-350 and determine the maximum tolerated dose (MTD) in children and young adults with relapsed solid tumors, including recurrent malignant brain tumors. All patients will receive BXQ-350 by intravenous (IV) infusion. The study is divided into two parts: Part...
What is the current status of trial NCT03967093?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 9 participants. The study started on 2019-04-15. Estimated completion is 2020-01-17.
What interventions are being tested in trial NCT03967093?
The interventions under investigation include: BXQ-350 (DRUG).
Who is sponsoring clinical trial NCT03967093?
This trial is sponsored by Bexion Pharmaceuticals, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.